Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer

This publication has 17 references indexed in Scilit:

• HER-2-positive metastatic breast cancer: trastuzumab and beyond
  Expert Opinion on Pharmacotherapy, 2008
• 111In-Labeled Trastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): An Auger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified Breast Cancer
  Journal of Nuclear Medicine, 2007
• Preparation and biological evaluation of 111In-, 177Lu- and 90Y-labeled DOTA analogues conjugated to B72.3
  Nuclear Medicine and Biology, 2007
• Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands
  Nuclear Medicine and Biology, 2007
• Overview of tyrosine kinase inhibitors in clinical breast cancer
  Endocrine-Related Cancer, 2005
• The experimental study on the radioimmunotherapy of the nasopharyngeal carcinoma overexpressing HER2/neu in nude mice model with intratumoral injection of 188Re-herceptin
  Nuclear Medicine and Biology, 2005
• Preclinical characterisation of ¹¹¹In‐DTPA‐trastuzumab
  British Journal of Pharmacology, 2004
• Mechanism of Action of Anti-Her2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2c4
  Published by Springer Nature ,2003
• Molecular targets for breast cancer therapy and prevention
  Nature Medicine, 2001
• Application of radioisotopes in the field of nuclear medicine
  Journal of Radioanalytical and Nuclear Chemistry, 1999